Absci Corporation (ABSI)
NASDAQ: ABSI · Real-Time Price · USD
3.570
+0.010 (0.28%)
At close: Dec 26, 2025, 4:00 PM EST
3.560
-0.010 (-0.28%)
After-hours: Dec 26, 2025, 7:39 PM EST
Absci Revenue
Absci had revenue of $378.00K in the quarter ending September 30, 2025, a decrease of -77.78%. This brings the company's revenue in the last twelve months to $6.68M, up 58.88% year-over-year. In the year 2024, Absci had annual revenue of $4.53M, down -20.71%.
Revenue (ttm)
$6.68M
Revenue Growth
+58.88%
P/S Ratio
162.12
Revenue / Employee
$17,930
Employees
157
Market Cap
536.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.53M | -1.18M | -20.71% |
| Dec 31, 2023 | 5.72M | -29.00K | -0.50% |
| Dec 31, 2022 | 5.75M | 965.00K | 20.18% |
| Dec 31, 2021 | 4.78M | 2.00K | 0.04% |
| Dec 31, 2020 | 4.78M | 2.72M | 132.04% |
| Dec 31, 2019 | 2.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ABSI News
- 12 days ago - Absci to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 17 days ago - Absci Corporation (ABSI) Discusses ABS-201 Program and Clinical Approach for Androgenetic Alopecia Transcript - Seeking Alpha
- 17 days ago - Absci Reports New Human Ex Vivo Data Demonstrating That ABS-201™ Stimulates Hair Growth and Regenerates Stem Cell Niche to Potentially Reverse Follicle Miniaturization - GlobeNewsWire
- 18 days ago - Absci and U.S. Soccer Legend Landon Donovan Partner to Champion the Patient Voice in Hair Loss Research - GlobeNewsWire
- 24 days ago - Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia - GlobeNewsWire
- 5 weeks ago - Absci Corporation (ABSI) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 6 weeks ago - Absci Corporation (ABSI) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Absci Reports Business Updates and Third Quarter 2025 Financial and Operating Results - GlobeNewsWire